IOL Chemicals & Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 17 May 2025
Result Summary
- IOL Chemicals & Pharmaceuticals Ltd reported a 3.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 14.2%.
- Its expenses for the quarter were down by 5.1% QoQ and 6.8% YoY.
- The net profit increased 34.5% QoQ and decreased 57.4% YoY.
- The earnings per share (EPS) of IOL Chemicals & Pharmaceuticals Ltd stood at 4.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 511.44 | 527.37 | 595.94 | -3.0% | -14.2% |
Total Expenses | 474.24 | 499.57 | 508.90 | -5.1% | -6.8% |
Profit Before Tax | 37.20 | 27.80 | 87.04 | 33.8% | -57.3% |
Tax | 9.58 | 7.27 | 22.26 | 31.8% | -57.0% |
Profit After Tax | 27.62 | 20.53 | 64.78 | 34.5% | -57.4% |
Earnings Per Share | 4.70 | 3.50 | 11.00 | 34.3% | -57.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
IOL Chemicals & Pharmaceuticals Ltd is a prominent player in the chemical and pharmaceutical industry, primarily engaged in the manufacture and sale of active pharmaceutical ingredients (APIs) and specialty chemicals. The company is known for its expertise in the production of Ibuprofen, a widely used analgesic and anti-inflammatory drug, which is one of their flagship products. In addition to APIs, IOL Chemicals & Pharmaceuticals also offers a range of specialty chemicals that cater to various industrial applications. As of the latest data, the company continues to be a significant contributor to the pharmaceutical sector, with a focus on expanding its product portfolio and market reach. Recent major developments or strategic shifts within the company are not available from the provided data.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), IOL Chemicals & Pharmaceuticals Ltd reported a total income of ₹511.44 crores, which represents a decrease of 3.0% from the preceding quarter (Q3FY25), where total income stood at ₹527.37 crores. Additionally, when compared year-over-year (YoY) to the fourth quarter of fiscal year 2024 (Q4FY24), the total income showed a significant decline of 14.2%, down from ₹595.94 crores. This decline in revenue on both a quarterly and yearly basis is evident from the figures provided, indicating a shift in sales or market conditions during these periods.
Profitability
The company's profitability metrics reveal a mixed performance for Q4FY25. Profit Before Tax (PBT) was reported at ₹37.20 crores, marking an increase of 33.8% from the previous quarter's ₹27.80 crores. However, on a YoY basis, PBT decreased by 57.3% from ₹87.04 crores in Q4FY24. After accounting for tax expenses, Profit After Tax (PAT) for Q4FY25 amounted to ₹27.62 crores, showing a QoQ growth of 34.5% from ₹20.53 crores in Q3FY25, yet reflecting a YoY decline of 57.4% from ₹64.78 crores in Q4FY24. The Earnings Per Share (EPS) followed a similar trend, increasing QoQ by 34.3% from ₹3.50 to ₹4.70, but decreasing YoY by 57.3% from ₹11.00. These figures highlight the variability in profitability over the observed periods.
Operating Metrics
Total expenses for IOL Chemicals & Pharmaceuticals Ltd in Q4FY25 were ₹474.24 crores, which signifies a reduction of 5.1% from the Q3FY25 figure of ₹499.57 crores. On a YoY basis, total expenses decreased by 6.8% from ₹508.90 crores in Q4FY24. This reduction in expenses, both quarterly and yearly, could impact the company's operating efficiency and cost management strategies. The tax expense for Q4FY25 was ₹9.58 crores, which increased by 31.8% QoQ from ₹7.27 crores in Q3FY25 but decreased by 57.0% YoY from ₹22.26 crores in Q4FY24. These operational metrics provide insights into the company's financial management and operational dynamics over the specified periods.